“Determining Therapeutic Efficacy in Breast Cancer Using Network-Based Global Chromatin Profile Fingerprinting”

NOTE day and location

Abstract: Regulatory abnormalities caused by epigenetic changes due to chromatin modifications are being increasingly recognized as contributors to cancer. While many molecularly targeted drugs have the potential to revert these modifications, their precise mechanism of action in cellular reprogramming is yet to be deciphered. To address this problem, we generated “network-based global chromatin profiling fingerprints” by integrating proteomic/phosphoproteomic, transcriptomic and regulatory genomic data to understand how unique chromatin alterations by post-translational histone modifications regulate cell state changes when treated with drugs in breast cancer. In this talk, I will describe how we use this network model to identify a histone mark as a key fingerprint, mediated by specific phosphoproteins and proto-oncogenes. We show specific drugs display selective inhibitory potential toward these phosphoproteins and proto-oncogenes, implicating them as potential therapeutic targets to restitute the identified histone’s status in breast cancer.

Department of Genetics seminars

For inquiries contact Debbie Peterson.